Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health

Carolyn Jack^{1

2

3}, Aaron M Drucker^{4

5}

Affiliations

¹ Divisions of Dermatology and Clinical Translational Research, Department of Medicine and Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
² McGill University Health Center (MUHC) Center for Atopic Dermatitis, Montreal, Quebec, Canada.
³ Infectious Diseases and Immunity in Global Health, Clinical Translational Biology, The Research Institute of the MUHC, Montreal, Quebec, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Medicine and Research and Innovation Institute, Women's College Hospital, Toronto, Ontario, Canada.

Carolyn Jack et al. J Eur Acad Dermatol Venereol. 2024 Nov.

. 2024 Nov;38(11):2053-2055.

doi: 10.1111/jdv.20356.

Carolyn Jack^{1

2

3}, Aaron M Drucker^{4

5}

¹ Divisions of Dermatology and Clinical Translational Research, Department of Medicine and Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
² McGill University Health Center (MUHC) Center for Atopic Dermatitis, Montreal, Quebec, Canada.
³ Infectious Diseases and Immunity in Global Health, Clinical Translational Biology, The Research Institute of the MUHC, Montreal, Quebec, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Medicine and Research and Innovation Institute, Women's College Hospital, Toronto, Ontario, Canada.

No abstract available

References

1. Reguiai Z, Becherel PA, Perrot JL, Boulard C, Fougerousse AC, Begon E, et al. Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study). J Eur Acad Dermatol Venereol. 2024;38:2149–2155.
1. Ravn NH, Ahmadzay ZF, Christensen TA, Larsen HHP, Loft N, Raevdal P, et al. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta‐analysis. J Am Acad Dermatol. 2021;85(2):453–461.
1. Shi VY, Chamberlain W, Siegfried E, Kraff‐Cooper C, Beckman K, Lio P, et al. Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: a review. J Am Acad Dermatol. 2023;89(2):309–315.
1. Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D, et al. Dupilumab‐associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78(8):2266–2276.
1. Thormann K, Luthi AS, Deniau F, Heider A, Cazzaniga S, Radonjic‐Hoesli S, et al. Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Allergy. 2024;79(4):937–948.